The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas

Journal of Infectious Diseases

Volumn 208, Issue 3, 2013, Pages 479-488

  Jepsen, Micha Phill Grønholm ^a,b,c   Jogdand, Prajakta S ^a,b,c   Singh, Susheel K ^b,c   Esen, Meral ^d,e   Christiansen, Michael ^a   Issifou, Saadou ^d,e   Hounkpatin, Aurore B ^d,e   Ateba Ngoa, Ulysse ^e   Kremsner, Peter G ^d,e   Dziegiel, Morten H ^c   Olesen Larsen, Severin ^a   Jepsen, Søren ^a   Mordmüller, Benjamin ^d,e   Theisen, Michael ^a,b,c  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e Centre de Recherches Médicales de Lambaréné HÔpital Albert Schweitzer   (Gabon)

Author keywords

ADCI; antibody; avidity; clinical trial; GLURP; GMZ2; immunity; MSP3; Plasmodium falciparum; vaccine

Indexed keywords

ALUMINUM HYDROXIDE; GMZ2 VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; LR 129; LR 130; LR 132; LR 55; LR 67; LR 68; MALARIA VACCINE; MR 186; MR 187; MR 188; RABIES VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADULT; ANTIBODY DEPENDENT CELLULAR INHIBITION; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CHILD; COMPARATIVE STUDY; DISEASE DURATION; DRUG SAFETY; DRUG TOLERABILITY; ETHNIC GROUP; ETHNICITY; GABONESE; GERMAN; HUMAN; IMMUNOGENICITY; MALARIA; MALARIA CONTROL; NONHUMAN; PEPTIDE MAPPING; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VACCINATION;

ADCI; ANTIBODY; AVIDITY; CLINICAL TRIAL; GLURP; GMZ2; IMMUNITY; MSP3; PLASMODIUM FALCIPARUM; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALUMINUM HYDROXIDE; ANTIBODIES, PROTOZOAN; CHILD, PRESCHOOL; HUMANS; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; VACCINES, SYNTHETIC;

EID: 84880225221     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit185     Document Type: Article

References (36)

1. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, Druilhe P. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 2000; 68:2617-20.
2. Borre MB, Dziegiel M, Hogh B, et al. Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle. Mol Biochem Parasitol 1991; 49:119-31.
3. McColl DJ, Silva A, Foley M, et al. Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Mol Biochem Parasitol 1994; 68:53-67.
4. Courtin D, Oesterholt M, Huismans H, et al. The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. PLoS One 2009; 4:e7590.
5. Dodoo D, Theisen M, Kurtzhals JA, et al. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 2000; 181:1202-5.
6. Theisen M, Dodoo D, Balde AT, et al. Selection of long GLURP synthetic peptides for vaccine development: antigenicity, relationship with clinical protection and immunogenicity. Infect Immun 2001; 69: 5223-9.
7. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 2004; 72:247-52.
8. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994; 84:1594-602.
9. Theisen M, Soe S, Jessing SG, et al. Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing. Vaccine 2000; 19:204-12.
10. Theisen M, Soe S, Oeuvray C, et al. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun 1998; 66:11-7.
11. Druilhe P, Spertini F, Soesoe D, et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2005; 2:e344.
12. Hermsen CC, Verhage DF, Telgt DS, et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 2007; 25:2930-40.
13. Carvalho LJ, Alves FA, Bianco C Jr., et al. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants. Clin Diagn Lab Immunol 2005; 12:242-8.
14. Esen M, Kremsner PG, Schleucher R, et al. Safety and immunogenicity of GMZ2-a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine 2009; 27:6862-8.
15. Mordmuller B, Szywon K, Greutelaers B, et al. Safety and immunoge-nicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. Vaccine 2010; 28:6698-703.
16. Belard S, Issifou S, Hounkpatin AB, et al. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLoS One 2011; 6:e22525.
17. Dahlback M, Jorgensen LM, Nielsen MA, et al. The chondroitin sulfate A-binding site of the VAR2CSA protein involves multiple N-terminal domains. J Biol Chem 2011; 286:15908-17.
18. Jepsen MP, Roser D, Christiansen M, et al. Development and evaluation of a multiplex screening assay for Plasmodium falciparum exposure. J Immunol Methods 2012; 384:62-70.
19. Theisen M, Soe S, Brunstedt K, et al. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine 2004; 22:1188-98.
20. Curtis KA, Kennedy MS, Charurat M, et al. Development and characterization of a bead-based, multiplex assay for estimation of recent HIV type 1 infection. AIDS Res Hum Retroviruses 2012; 28:188-97.
21. Ofori MF, Staalsoe T, Bam V, et al. Expression of variant surface antigens by Plasmodium falciparum parasites in the peripheral blood of clinically immune pregnant women indicates ongoing placental infection. Infect Immun 2003; 71:1584-6.
22. Jogdand PS, Singh SK, Christiansen M, Dziegiel MH, Singh S, Theisen M. Flow cytometric readout based on Mitotracker Red CMXRos staining of live asexual blood stage malarial parasites reliably assesses antibody dependent cellular inhibition. Malar J 2012; 11:235.
23. Moll Kirsten LI, Perlmann Hedvig, Scherf Artur, Wahlgren Mats. Methods in Malaria Research. Available at: http://www.biomalpar.org/updatedMethods-In- Malaria-Research-5thedition.pdf. Accessed 10 May 2013.
24. Audran R, Cachat M, Lurati F, et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 2005; 73:8017-26.
25. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisid-dhi T, Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 1990; 172:1633-41.
26. Mullen GE, Ellis RD, Miura K, et al. Phase 1 trial of AMA1-C1/Alhy-drogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One 2008; 3:e2940.
27. Singh S, Soe S, Mejia JP, et al. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J Infect Dis 2004; 190:1010-8.
28. Stanisic DI, Martin LB, Gatton ML, Good MF. Inhibition of 19-kDa C-terminal region of merozoite surface protein-1-specific antibody responses in neonatal pups by maternally derived 19-kDa C-terminal region of merozoite surface protein-1-specific antibodies but not whole parasite-specific antibodies. J Immunol 2004; 172:5570-81.
29. Nebie I, Diarra A, Ouedraogo A, et al. Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso. Parasite Immunol 2009; 31:474-80.
30. Tamborrini M, Stoffel SA, Westerfeld N, et al. Immunogenicity of a vi-rosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malar J 2011; 10:359.
31. Lousada-Dietrich S, Jogdand PS, Jepsen S, et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and type 1 cellular immune responses against GMZ2-a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 2011; 29:3284-92.
32. Poland GA, Jacobson RM, Colbourne SA, et al. Measles antibody sero-prevalence rates among immunized Inuit, Innu and Caucasian subjects. Vaccine 1999; 17:1525-31.
33. Rager-Zisman B, Bazarsky E, Skibin A, et al. Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children. Clin Diagn Lab Immunol 2004; 11:913-8.
34. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 se-rogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281:1520-7.
35. Kimman TG, Vandebriel RJ, Hoebee B. Genetic variation in the response to vaccination. Community Genet 2007; 10:201-17.
36. Esen M, Mordmuller B, de Salazar PM, et al. Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura. Vaccine 2012; 30:7621-4. Partnership Association